CELLect Horizons: Moving the Needle in Hematological Malignancies provides a comprehensive analysis of the advancements in CAR-T therapies for hematological malignancies, focusing on next-generation CAR-Ts that go beyond CD19 and BCMA targets. The report, authored by Sami Corwin, Ph.D., highlights several key areas of innovation and their potential impact on the treatment landscape for patients with liquid tumors.

Approved CAR-T therapies have significantly transformed the treatment of certain liquid tumors, generating $4.3 billion in global sales in 2024. However, all seven approved CAR-T therapies target CD19 or BCMA, which are unsuitable for several hematological malignancies, leaving many patients without approved CAR-T options. Additionally, a significant percentage of patients relapse within 12 months of treatment, indicating a need for more effective therapies.

Overall, the report provides a thorough analysis of the current state and future potential of CAR-T therapies in hematological malignancies, emphasizing the need for continued innovation to unlock these therapies’ significant untapped commercial potential.

Further key observations in the report are highlighted below:

  • Innovative targets: New antigen targets, such as GPRC5D and CD7, which have shown promising clinical responses
  • Multi-targeting CAR-Ts: The potential of dual and tri-targeting CAR-T therapies to combat antigen loss and improve patient outcomes
  • Allogeneic CAR-Ts: Genetic modifications that could enable off-the-shelf CAR-T therapies to reach their full potential, increasing accessibility and reducing costs
  • Modular CAR-Ts: A unique approach to conventional CAR-Ts, providing increased control over CAR-T expansion and associated toxicities
  • Clinical data: Detailed clinical data from various CAR-T cell programs, highlighting response rates, durability, and safety profiles
  • Market potential: Projections of significant growth in CAR-T therapies, with sales expected to reach at least $12.6 billion by 2030, driven by increased penetration in second-line multiple myeloma and the approval of subsequent CAR-T therapies

For more information about our biotech research, please contact us or your William Blair representative.